Daxas (roflumilast) has been recognised by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in its COPD management guidelines.
A section on a new class of drugs, phosphodiesterase 4 (PDE4) inhibitors, describes the efficacy of roflumilast in patients with COPD.
‘The Global Strategy for Diagnosis, Management and Prevention of COPD’, provides evidence-based guidelines for COPD management and is updated annually by a committee of leading COPD experts.
It states that roflumilast “reduces exacerbations treated with oral glucocorticosteroids”, adding: “these effects are also seen when roflumilast is added to long-acting bronchodilators”.
Peter Calverley, Professor of Respiratory Medicine, University of Liverpool, said: “Despite current maintenance therapies, COPD remains a significant area of unmet medical need. As it progresses, patients suffer exacerbations or lung attacks when breathing can become extremely difficult and they may have to be admitted to hospital.
“Studies have shown that the PDE4 inhibitor, roflumilast, significantly reduces exacerbations. The GOLD guidelines recognise its contribution to the management of this debilitating disease and it is important that physicians who treat COPD have this information.”
Daxas has been launched in Germany, Denmark and the UK, and is scheduled to be launched in other markets in 2011.